Table 4

Effect of T-705 on infectious virus yield and viral RNA copy number during serial passage in MDCK cells inoculated with a high dose of 2009 pandemic influenza A (H1N1) virusa

H1N1 virusPassageInfectious virus yield (log10 PFU/ml)bVirus RNA copy no. (log10 genome copies/ml)cSpecific infectivity (infectious virus yield/viral RNA copy no.)d
Mock treatmentT-705 treatmentMock treatmentT-705 treatmentMock treatmentT-705 treatment
A/Denmark/524/200907.1 ± 0.09NAe9.4 ± 0.07NA0.8 ± 0.08NA
17.3 ± 0.055.4 ± 0.11**8.3 ± 0.648.2 ± 0.640.9 ± 0.350.7 ± 0.75
25.6 ± 0.273.8 ± 0.12**6.0 ± 0.435.1 ± 0.300.9 ± 0.350.7 ± 0.21
34.2 ± 0.11<1.0**5.9 ± 0.393.5 ± 0.12*0.7 ± 0.250.3 ± 0.12
43.7 ± 0.16<1.0**5.5 ± 0.37<3.0**0.7 ± 0.27<0.3
A/Denmark/528/200907.0 ± 0.10NA9.2 ± 0.24NA0.8 ± 0.17NA
16.6 ± 0.035.9 ± 0.827.8 ± 0.617.8 ± 0.630.8 ± 0.320.8 ± 0.73
24.8 ± 0.033.8 ± 0.125.6 ± 0.445.5 ± 0.370.9 ± 0.240.7 ± 0.25
33.2 ± 0.03<1.0*4.7 ± 0.223.0 ± 0.10*0.7 ± 0.130.3 ± 0.10
41.4 ± 0.91<1.04.2 ± 0.5<3.0**0.3 ± 0.71<0.3
  • a *, P < 0.01, or **, P < 0.0001, significant differences with respect to mock-treated samples by two-way ANOVA.

  • b Infectious virus was titrated by plaque assay in MDCK cells. Values are means ± SD from three independent experiments.

  • c Virus RNA copy number was determined by quantitative real-time PCR of the matrix gene. Values are means ± SD from three independent experiments.

  • d Infectious virus yield × 10−3/genome copy number, determined 24 h p.i.

  • e NA, not applicable.